(UroToday.com) Docetaxel is a standard-of-care chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) patients that may potentiate antitumor immune responses, thus supporting its use in combination with nivolumab, which has shown limited antitumor activity in mCRPC as monotherapy. CheckMate 9KD (NCT03338790) is a phase 2 trial of nivolumab in combination with rucaparib, docetaxel, or enzalutamide for patients with mCRPC. An earlier interim analysis from CheckMate 9KD showed encouraging efficacy of the combination of nivolumab plus docetaxel with no new safety signals versus historical data with nivolumab and docetaxel alone. At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Dr. Karim Fizazi and colleagues presented the final analysis results for CheckMate 9KD Arm B (nivolumab plus docetaxel) of CheckMate 9KD.